Sunday, June 15, 2025

Latest

PharmaCielo Receives Approval For US$3 Million Import Contract

PharmaCielo Ltd (TSXV: PCLO) has become one of the first venture listed equities to receive approval for the importation of cannabidiol isolate to the United States. The company announced this morning that the exchange has finally granted the approval, which will allow the company to fulfill its previously announced supply agreement.

The supply agreement, announced in late September 2019, was anticipated to be fulfilled by the end of the year as per the original text of the release. This was delayed however as a result of requiring exchange approval for the transaction. The contract stipulates that medicinal grade CBD isolate was to be provided to General Extract, LLC.

In total, the contract itself is for US$3 million, which marks the firms entry to the American market in a significant way. The isolate, which conforms to US Farm Bill standards, is expected to begin arriving in the current quarter to the supplier, with all product being shipped from Columbia.

The venture exchange has approved the company for the importation of up to US$3.0 million in hemp derived CBD isolate to the United States. Any further quantities will require addition venture approval.

PharmaCielo last traded at $3.54 on the TSX Venture.


Information for this briefing was found via Sedar and PharmaCielo Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Silver: The Santa Elena Mine

Equinox Gold: Guidance Cut After Issues At Greenstone

Simply Solventless Q4 Earnings: So Much For Guidance

Recommended

NexGen Energy Receives Approval For Site Expansion At Rook I Project

ESGold Sees Installation Of Humphrey Spirals Completed At Montauban

Related News

PharmaCielo Sees Marc Lustig Appointed As Lead Director, Conducts $10 Million Financing

It appears that PharmaCielo Ltd (TSXV: PCLO) has effectively locked in a new lead director....

Tuesday, November 3, 2020, 08:45:53 AM

PharmaCielo Records $0.4 Million In Revenue, $7.2 Million Net Loss In Q2 2021

PharmaCielo Ltd. (TSXV: PCLO) reported today its financial performance for the quarter ending June 30,...

Friday, August 20, 2021, 09:08:00 AM

PharmaCielo Third Quarter Revenues Crater 97.9%, CEO Forced Out

PharmaCielo Ltd (TSXV: PCLO) this morning filed its third quarter financial results, posting brutal revenues...

Monday, November 30, 2020, 08:34:11 AM

PharmaCielo Conducts $4.0 Million Bought Deal Financing

PharmaCielo Ltd (TSXV: PCLO) is the latest firm to announce a bought deal financing. The...

Wednesday, June 10, 2020, 08:32:24 AM

Pharmacielo Latest Target of Hindenburg Research

Pharmacielo Ltd (TSXV: PCLO) is the latest target of short sellers Hindenburg Research, with Hindenburg...

Monday, March 2, 2020, 09:39:09 AM